首页> 美国卫生研究院文献>Clinical and Translational Science >Current Status and Open Issues Concerning Global Clinical Trials (GCTs) in Japan and East Asia
【2h】

Current Status and Open Issues Concerning Global Clinical Trials (GCTs) in Japan and East Asia

机译:日本和东亚地区全球临床试验(GCT)的现状和未解决的问题

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

When global clinical trials are carried out, it is important to consider the influence of racial and ethnic differences on the outcome. From this viewpoint, global clinical trials in East Asia, where racial differences are estimated to be small, are now attracting close attention. Under such circumstances, we conducted a survey using the data registered with ClinicalTrial.gov to investigate the status of participation of East Asian countries in global clinical trials and differences in the regions selected for drug development between Japanese enterprises and non‐Japanese enterprises. This survey revealed that about 90% of all global clinical trials and those involving East Asian countries were sponsored by non‐Japanese enterprises. Global clinical trials involving only East Asia have been accepted as one of the development strategies by Japanese enterprises, but this strategy has not spread widely among non‐Japanese enterprises.
机译:在进行全球临床试验时,重要的是要考虑种族和种族差异对预后的影响。从这个角度来看,估计种族差异很小的东亚地区的全球临床试验现在正受到密切关注。在这种情况下,我们使用在ClinicalTrial.gov上注册的数据进行了调查,以调查东亚国家参与全球临床试验的状况以及在日本企业和非日本企业之间选择的药物开发区域之间的差异。这项调查显示,在所有全球临床试验中以及涉及东亚国家的临床试验中,约有90%由非日本企业赞助。日本企业已将仅涉及东亚地区的全球临床试验作为发展战略之一,但该战略并未在非日本企业中广泛传播。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号